- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Roche Canada, pan-Canadian Pharmaceutical Alliance complete negotiations for VABYSMO to treat Neovascular neovascular AMD, DME
VABYSMO is a humanized bispecific immunoglobulin G1(IgG1) antibody that acts through inhibition of both Ang-2 and vascular endothelial growth factor A (VEGF-A).
Mississauga: Hoffmann-La Roche Limited (Roche Canada) has announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for VABYSMO (faricimab injection), indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME), two of the leading causes of vision loss among Canadians. “Securing...
Mississauga: Hoffmann-La Roche Limited (Roche Canada) has announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for VABYSMO (faricimab injection), indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD) and diabetic macular edema (DME), two of the leading causes of vision loss among Canadians.
Read also: USFDA accepts application for Roche Vabysmo for retinal vein occlusion treatment
Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751